class="xn-location">the United States and European Union demonstrated that ETHICON™ OMNEX™ provided hemostasis three times faster than oxidized regenerated cellulose at a rate of 1.99 minutes vs 6.73 minutes, with 54 percent of the ETHICON™ OMNEX™ patients receiving immediate hemostasis.(2) There were no significant differences in adverse events compared to oxidized regenerated cellulose during the study time period and 4+ year follow-up analysis.(2)
ETHICON™ OMNEX™ Surgical Sealant has proven efficacy in a broad spectrum of vascular reconstructive procedures including arteriovenous access, aortobifemoral bypass, femoral popliteal bypass, endarterectomy, abdominal aortic aneurysm and aortotomies.(1)
ETHICON™ OMNEX™ Surgical Sealant is contraindicated in patients with known hypersensitivity to cyanoacrylate or formaldehyde. The device is not for intravascular use. ETHICON™ OMNEX™ Surgical Sealant is intended for use as an adjunctive sealant and is not to be used in place of sutures, staples, or mechanical closure.
About ETHICON™ Biosurgery
Ethicon, Inc.'s Biosurgery Business, with nearly 50 years of proven experience in hemostasis, continues its dedication with cutting edge technologies that are supported by evidence.
Ethicon, Inc. is committed to advancing the future of biosurgery. Ethicon, Inc. offers the world's most complete line of absorbable hemostats, including proprietary oxidized, regenerated cellulose hemostats, absorbable gelatin powder and sponges, a hemostatic matrix, topical human thrombin, and human fibrin sealant.
About Ethicon, Inc.
Ethicon, Inc., a Johnson & Johnson company, is a trusted, world-wide leader in surgical care.
'/>"/>
SOURCE Ethicon, Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 Related medicine technology :1.
Samplify Expands Global Presence; Opens China Office2.
Millennium Pharmacy Expands in New Jersey3.
Max Neeman International Expands Data Management Services with Conversion Into CDISC Standard Data Model4.
Action Fabricators Expands its Footprint in the Healthcare Industry With the Launch of Laminin Medical Products5.
Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc.6.
Advanced Life Sciences Expands Collaboration with U.S. Government to Study Restanza(TM) as Treatment for Sexually Transmitted Infections7.
MoleSafe USA Expands Services to Leading Cancer Facilities at St. Josephs/Candler and CentraState Medical Center8.
Waters Expands Xevo MS Instrument Platform With Next-Generation Mass Spectrometers9.
West Haven Firm Expands Biomedical Disposal Program with Community Economic Development Fund10.
Connectyx Retains Services of CP Capital Securities as It Expands Its Presence in the $5 Billion US Electronic Health Record Market11.
SynCo Expands Agreement with OncoMed Pharmaceuticals to Manufacture Cancer Stem Cell Antibodies